Doug Osman helps pharma manufacturers unlock more from their processes

For Alfa Laval's Doug Osman, helping customers navigate this changing landscape is what makes the industry so rewarding. Working with some of the world's leading pharmaceutical companies, he supports efforts to improve production processes, increase efficiency, and bring innovations from development to commercial scale. 

"Pharmaceutical manufacturing is a relatively young industry compared to many others," says Doug. "Penicillin only became widely available around 80 years ago, and insulin manufacturing has evolved dramatically over the past few decades. We're still learning, innovating, and finding new ways to improve how medicines are produced." 

A personal commitment to improving access 

Doug's interest in pharmaceutical manufacturing is driven in part by personal experience. 

"I have family members who could have benefited from treatments if they had been developed earlier or made more widely available," he says. "If we can help customers get more from their existing facilities and processes, we can contribute to improving access to medicines for people in need. That's a powerful motivator." 

He enjoys tackling complex manufacturing challenges where solutions are not immediately obvious. 

"The best results often come from collaboration," says Doug. "By working closely with customers, discussing challenges openly, and looking at problems from different angles, we can often identify opportunities that weren't obvious at first." 

Understanding industry trends 

Working closely with pharmaceutical manufacturers gives Doug firsthand visibility into the trends shaping the industry. 

One area attracting significant attention is process intensification, where manufacturers increase product concentration within a process to improve productivity and make better use of existing facilities. 

"Increasing production without expanding a facility can deliver significant benefits," Doug explains. "Higher product concentrations allow manufacturers to increase output, reduce the number of batches required, lower operating costs, and improve sustainability." 

This additional flexibility helps manufacturers respond more effectively to changing demand while maximizing the value of their existing infrastructure. 

Supporting process intensification through separation expertise 

According to Doug, Alfa Laval is well positioned to support process intensification through its expertise in centrifugal separation. 

In bioprocessing applications, efficient cell retention and media management are essential for maintaining high cell concentrations and maximizing productivity. Advanced centrifuge technology can help manufacturers remove spent media while retaining valuable cells, supporting improved process performance, and providing higher yields. 

"At its core, this is a separation challenge," says Doug. "That's where Alfa Laval's expertise can make a real difference. The ability to efficiently handle both media and concentrated cell suspensions continuously enables customers to optimize operating conditions and increase process performance." 

By helping manufacturers increase cell concentrations while reducing process limitations, these solutions can support greater productivity, improved facility utilization, and more efficient operations. 

Reducing environmental impact 

Sustainability is a key priority across pharmaceutical manufacturing. While the industry is often viewed as resource-intensive, many manufacturers are actively working to reduce their environmental footprint and improve operational efficiency. 

"Many of our customers share our own ambition to improve sustainability in operations," says Doug. "They're focused on reducing resource consumption and operating responsibly, and that's an area where Alfa Laval can provide meaningful support." 

One example is the use of single-use technologies. Although single-use plastics are often viewed negatively in everyday applications, they can deliver important sustainability benefits in pharmaceutical production. 

By eliminating the need for extensive cleaning between batches, single-use systems can significantly reduce water, energy, chemical use, and production downtime. 

"In pharmaceutical manufacturing, single-use technologies can improve flexibility, productivity, and speed to market," says Doug. "Because cleaning cycles are minimized, manufacturers can switch between products more quickly while maintaining patient safety and preventing cross-contamination. Between batches" 

The simplified changeover process also allows production lines to be adapted more efficiently. When managed responsibly, many single-use materials can be recycled or repurposed through dedicated waste-management programs, with re-cycle and responsible disposal rates much higher than other plastics. 

Single-use technologies can also help manufacturers bring new products to market faster. Traditional facilities often require lengthy construction, validation, and qualification processes before production can begin. In contrast, single-use systems can typically be deployed and scaled more quickly closer to patient populations, helping manufacturers make better use of limited patent exclusivity periods. 

"Single-use solutions provide flexibility when establishing new process lines and can accelerate the path to commercial production," says Doug. "They also make technology transfer to contract manufacturing partners more straightforward." 

The benefits extend beyond operational efficiency and financial performance. 

"Ultimately, faster and more efficient manufacturing means medicines can reach patients sooner," says Doug. "That's where the real impact is made." 

Significant potential ahead 

At its core, pharmaceutical manufacturing is about improving patients' lives. While commercial success is essential, the industry's broader purpose is to develop and deliver medicines that address unmet medical needs. 

For Doug, that mission is what makes the sector so compelling. 

"Many diseases still lack effective treatment, and there are thousands of drug candidates currently being developed," he says. "Pharmaceutical companies continue to invest heavily in research and development, which creates tremendous opportunities to bring new therapies to patients." 

Doug also sees the industry evolving as manufacturers increasingly focus on specialized therapies designed for smaller patient populations. While blockbuster drugs remain important, growth is increasingly being driven by targeted treatments that require more flexible and efficient manufacturing approaches. 

Advances in cell and gene therapies, peptide-based medicines, and mRNA technologies are accelerating this trend, creating new opportunities while introducing additional production and supply chain complexities. Each modality brings unique manufacturing requirements, increasing the need for scalable and adaptable processing solutions. 

"The industry is constantly evolving," says Doug. "Forty years ago, biologic production relied primarily on hosts such as yeast and E. coli. Today, mammalian cell cultures play a major role, and new expression systems continue to emerge as companies develop increasingly complex therapies. At the same time, we're seeing significant growth in areas like peptides and mRNA, which are expanding the range of treatments available to patients and creating new manufacturing challenges to solve." 

Turning innovation into production 

As new therapies become more sophisticated, manufacturers need production platforms capable of supporting the next generation of biologics and advanced treatments. 

According to Doug, this is where process expertise becomes especially valuable. 

"Our customers are developing innovative science every day," he says. "The challenge is often turning that innovation into a robust, scalable manufacturing process. That's where we can help." 

By combining equipment expertise with a deep understanding of pharmaceutical processes, Alfa Laval works with manufacturers to move efficiently from development to commercial production. 

"The science belongs to our customers," Doug explains. "Our role is to help translate that science into practical, reliable manufacturing solutions that can deliver therapies to patients at scale." 

This combination of innovation, collaboration, and process optimization is what Doug believes will continue to drive the future of pharmaceutical manufacturing